Jun-Qing Gao1, Wei Yang1, Zong-Jun Liu2. 1. Department of Cardiology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China. 2. Department of Cardiology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China. lzj160507@163.com.
Abstract
BACKGROUND: Renal denervation (RDN) is as an effective treatment for heart failure (HF), but its effects on cardiac function of patients with HF are not well documented. Here, the aim was to investigate RDN's effect on patients with chronic systolic HF, by conducting a single-center, prospective, randomized, and controlled study. METHODS:Sixty patients with chronic systolic HF were randomly assigned to the RDN or control groups, receiving percutaneous catheter-based RDN with radiofrequency ablation and drug treatment, respectively. All patients performed a 6-minute walk test, echocardiography, blood pressure measurement, and biochemical test, at both baseline and in a 6-month follow up. RESULTS: Over 6-month follow up, patients in RDN group showed a decrease in N-terminal pro-B-type natriuretic peptide (440.1 ± 226.5 pg/mL vs. 790.8 ± 287.0 pg/mL, p < 0.001, Cohen's d = 1.14), an increase in left ventricular ejection fraction (39.1 ± 7.3% vs. 35.6 ± 3.3%, p = 0.017, Cohen's d = 0.61), improved New York Heart Association class assessment (p = 0.01, Cohen's d = 0.66), and decreased blood pressures (p < 0.001, Cohen's d = 0.91), without reporting hypotension and syncope amaurosis. No significant between-group difference was observed for glomerular filtration rate and heart rate. CONCLUSIONS: Renal denervation which effectively and safely improves patient's cardiac function as well as exercise tolerance, could be considered as an effective treatment for chronic systolic HF.
RCT Entities:
BACKGROUND: Renal denervation (RDN) is as an effective treatment for heart failure (HF), but its effects on cardiac function of patients with HF are not well documented. Here, the aim was to investigate RDN's effect on patients with chronic systolic HF, by conducting a single-center, prospective, randomized, and controlled study. METHODS: Sixty patients with chronic systolic HF were randomly assigned to the RDN or control groups, receiving percutaneous catheter-based RDN with radiofrequency ablation and drug treatment, respectively. All patients performed a 6-minute walk test, echocardiography, blood pressure measurement, and biochemical test, at both baseline and in a 6-month follow up. RESULTS: Over 6-month follow up, patients in RDN group showed a decrease in N-terminal pro-B-type natriuretic peptide (440.1 ± 226.5 pg/mL vs. 790.8 ± 287.0 pg/mL, p < 0.001, Cohen's d = 1.14), an increase in left ventricular ejection fraction (39.1 ± 7.3% vs. 35.6 ± 3.3%, p = 0.017, Cohen's d = 0.61), improved New York Heart Association class assessment (p = 0.01, Cohen's d = 0.66), and decreased blood pressures (p < 0.001, Cohen's d = 0.91), without reporting hypotension and syncope amaurosis. No significant between-group difference was observed for glomerular filtration rate and heart rate. CONCLUSIONS: Renal denervation which effectively and safely improves patient's cardiac function as well as exercise tolerance, could be considered as an effective treatment for chronic systolic HF.
Authors: Murray D Esler; Henry Krum; Paul A Sobotka; Markus P Schlaich; Roland E Schmieder; Michael Böhm Journal: Lancet Date: 2010-11-17 Impact factor: 79.321
Authors: Markus P Schlaich; Flora Socratous; Sarah Hennebry; Nina Eikelis; Elisabeth A Lambert; Nora Straznicky; Murray D Esler; Gavin W Lambert Journal: J Am Soc Nephrol Date: 2008-09-17 Impact factor: 10.121
Authors: Felix Mahfoud; Daniel Urban; Desiree Teller; Dominik Linz; Philipp Stawowy; Jan-Hendrik Hassel; Peter Fries; Stephan Dreysse; Ernst Wellnhofer; Günther Schneider; Arno Buecker; Christopher Schneeweis; Adelina Doltra; Markus P Schlaich; Murray D Esler; Eckart Fleck; Michael Böhm; Sebastian Kelle Journal: Eur Heart J Date: 2014-03-06 Impact factor: 29.983
Authors: Justin E Davies; Charlotte H Manisty; Ricardo Petraco; Anthony J Barron; Beth Unsworth; Jamil Mayet; Mohamad Hamady; Alun D Hughes; Peter S Sever; Paul A Sobotka; Darrel P Francis Journal: Int J Cardiol Date: 2012-09-29 Impact factor: 4.164
Authors: Deepak L Bhatt; David E Kandzari; William W O'Neill; Ralph D'Agostino; John M Flack; Barry T Katzen; Martin B Leon; Minglei Liu; Laura Mauri; Manuela Negoita; Sidney A Cohen; Suzanne Oparil; Krishna Rocha-Singh; Raymond R Townsend; George L Bakris Journal: N Engl J Med Date: 2014-03-29 Impact factor: 91.245
Authors: Hitesh C Patel; Stuart D Rosen; Carl Hayward; Vassilios Vassiliou; Gillian C Smith; Ricardo R Wage; James Bailey; Ronak Rajani; Alistair C Lindsay; Dudley J Pennell; S Richard Underwood; Sanjay K Prasad; Raad Mohiaddin; J Simon R Gibbs; Alexander R Lyon; Carlo Di Mario Journal: Eur J Heart Fail Date: 2016-03-16 Impact factor: 15.534
Authors: Zhiqiu Xia; Li Han; Peter R Pellegrino; Alicia M Schiller; Logan D Harrold; Robert L Lobato; Steven J Lisco; Irving H Zucker; Han-Jun Wang Journal: Heliyon Date: 2022-01-31